Status:
RECRUITING
Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Acute Kidney Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE1
PHASE2
Brief Summary
Acute kidney injury (AKI) is increasing worldwide in recent years and is a major risk factor of chronic kidney disease (CKD). AKI, acute kidney disease (AKD) and CKD form a continuum whereby initial k...
Detailed Description
Acute kidney injury (AKI) is increasing worldwide in recent years and is a major risk factor of chronic kidney disease (CKD). An episode of AKI is not only associated with significant risk of short- a...
Eligibility Criteria
Inclusion
- Patient with cardiac surgery associated-AKI, stage 2 and stage 3
Exclusion
- Chronic kidney disease
- Decompensated heart failure (EF \< 45%)
- Liver cirrhosis, child B or C
- Acute infection
- Acute bleeding
- Long-term use of immunosuppressant other than azacitidine
- Patients with active cancer other than acute leukemia or myelodysplastic syndrome
- Leukopenia, anemia or thrombocytopenia
- Pregnancy
Key Trial Info
Start Date :
April 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05325099
Start Date
April 18 2024
End Date
May 31 2026
Last Update
February 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yu Hsiang Chou
Taipei, Taiwan, 116